Swiss National Bank Has $2.83 Million Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN)

Swiss National Bank grew its position in Myriad Genetics, Inc. (NASDAQ:MYGNGet Rating) by 2.2% during the 4th quarter, Holdings reports. The firm owned 194,700 shares of the company’s stock after purchasing an additional 4,200 shares during the period. Swiss National Bank’s holdings in Myriad Genetics were worth $2,825,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in MYGN. Boston Partners bought a new stake in Myriad Genetics in the 4th quarter valued at $64,000. Arizona State Retirement System boosted its position in shares of Myriad Genetics by 4.2% in the fourth quarter. Arizona State Retirement System now owns 22,753 shares of the company’s stock valued at $330,000 after acquiring an additional 920 shares during the period. Duality Advisers LP acquired a new position in shares of Myriad Genetics in the fourth quarter valued at about $767,000. Fisher Asset Management LLC increased its position in Myriad Genetics by 51.0% during the fourth quarter. Fisher Asset Management LLC now owns 190,383 shares of the company’s stock worth $2,762,000 after acquiring an additional 64,276 shares during the period. Finally, ProShare Advisors LLC raised its stake in Myriad Genetics by 8.8% in the 4th quarter. ProShare Advisors LLC now owns 19,298 shares of the company’s stock worth $280,000 after purchasing an additional 1,554 shares in the last quarter. Institutional investors own 99.08% of the company’s stock.

Myriad Genetics Stock Performance

Shares of MYGN stock opened at $22.68 on Wednesday. Myriad Genetics, Inc. has a fifty-two week low of $13.92 and a fifty-two week high of $28.18. The stock’s fifty day moving average price is $21.67 and its two-hundred day moving average price is $19.88. The company has a market cap of $1.85 billion, a PE ratio of -12.60 and a beta of 1.84.

Myriad Genetics (NASDAQ:MYGNGet Rating) last released its quarterly earnings data on Wednesday, May 3rd. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The business had revenue of $181.20 million during the quarter, compared to analyst estimates of $171.56 million. Myriad Genetics had a negative net margin of 21.05% and a negative return on equity of 7.42%. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period last year, the business earned ($0.14) earnings per share. On average, equities analysts predict that Myriad Genetics, Inc. will post -0.63 EPS for the current fiscal year.

Insider Activity at Myriad Genetics

In related news, COO Nicole Lambert sold 6,433 shares of the stock in a transaction that occurred on Monday, March 27th. The shares were sold at an average price of $23.48, for a total value of $151,046.84. Following the completion of the transaction, the chief operating officer now owns 240,506 shares of the company’s stock, valued at approximately $5,647,080.88. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.00% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Stephens increased their target price on shares of Myriad Genetics from $17.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Monday, March 6th. Raymond James increased their price target on Myriad Genetics from $25.00 to $27.00 and gave the stock an “outperform” rating in a research report on Friday, March 3rd. started coverage on Myriad Genetics in a report on Thursday, May 18th. They issued a “hold” rating for the company. Finally, The Goldman Sachs Group raised Myriad Genetics from a “sell” rating to a “buy” rating and increased their target price for the stock from $18.00 to $25.00 in a report on Tuesday. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from, Myriad Genetics presently has an average rating of “Hold” and an average price target of $26.60.

Myriad Genetics Company Profile

(Get Rating)

Myriad Genetics, Inc engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk of developing a disease later in life.

Further Reading

Want to see what other hedge funds are holding MYGN? Visit to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGNGet Rating).

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with's FREE daily email newsletter.